Dicot continues to stay on schedule in its clinical phase I study. In January, the company, which is developing the next generation of potency drugs, was able to make a first positive data reading from the study, and now the last participant in the trial has been recruited.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/03/dicots-phase-i-study-fully-recruited/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/dicot-ab--publ-/r/biostock--dicot-s-phase-i-study-fully-recruited,c3945253

(c) 2024 Cision. All rights reserved., source Press Releases - English